Pharmaco - Today Stories

Heidelberg Pharma Announces First Patient Dosed with Antibody Targeted Amanitin Conjugate HDP-101 in Multiple Myeloma Ladenburg, Germany, 15 February 2022 - Heidelberg Pharma AG (FSE: HPHA) today announced that the first patient has been dosed with HDP-101 in a Phase I/IIa study at the Winship Cancer Institute of Emory University, Atlanta, GA, USA. The open-label, multi-center Phase I/IIa study will evaluate HDP-101, a BCMA antibody-Amanitin conjugate, for the treatment of relapsed or refractory multiple myeloma, a bone marrow cancer with high unmet medical need. Dr. András Strassz, Chief Medical Officer of Heidelberg Pharma, commented: "It is an important step for Heidelberg Pharma to have the first patient dosed in our study. This Phase I/IIa study will test a new mode of action in oncol…

The Cell and Gene Therapy Catapult has partnered with MICA Biosystems to begin the journey of bringing their revolutionary regenerative medicine technology to the MHRA. London 10th February 2022: The Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation specialising in the advancement of cell and gene therapies, announces a collaboration with MICA Biosystems (MICA), a Birmingham based medical technology company, to leverage the expertise of the CGT Catapult in taking novel technologies and concepts through to clinical trials. MICA have developed a ground-breaking platform that uses patented nanotechnology to control a patient’s stem cells, in situ, to repair or replace damaged or diseased tissue. The first application of MICA’s technology is i…

Arrangement Includes Labcorp’s Acquisition of Certain Outreach Laboratory Assets Strategic Collaboration Expands Patient Access to Labcorp’s Services, Drives Efficiencies and Advances Clinical Innovation BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has entered into agreements to create a comprehensive strategic relationship with Ascension, one of the nation’s leading Catholic and non-profit health systems. Through the expansive strategic collaboration, Labcorp will manage Ascension’s hospital-based laboratories in 10 states and purchase select assets of the health system’s outreach laboratory business. This long-term relationship will expand Labcorp’s clinical laboratory services in several states across the countr…

Paris, February 8, 2022. Sanofi announced today the completion of its acquisition of Amunix Pharmaceuticals, Inc, adding a promising pipeline of T-cell engagers and cytokine therapies. The acquisition also provides access to Amunix Pro-XTEN, XPAT, and XPAC technology to deliver next generation Conditionally Activated Biologics. The technology platform is highly complementary to Sanofi’s existing R&D platforms and supports Sanofi’s efforts to accelerate and expand its contributions to innovative medicines for oncology patients, with approximately 20 molecules currently in development. Weil, Gotshal & Manges LLP is acting as Sanofi’s legal counsel. Centerview Partners LLC is acting as financial advisor to Amunix and Fenwick & West LLP is acting as its legal counsel. About SanofiW…

Ortenberg, 7th February 2022. BMG LABTECH introduced the new VANTAstarTM microplate reader, further expanding its range of high-quality, made-in-Germany instruments. The latest addition to the BMG LABTECH portfolio, the VANTAstar was conceived for ease-of-use and flexibility for a wide range of applications in basic research and life sciences. The VANTAstar was officially introduced to public at the SLAS 2022 conference and exhibition in Boston, USA. Flexible microplate reader with simplified workflows The VANTAstar is a compact multi-mode microplate reader and is equipped with three features that enable an effortless detection setup and improve data quality: Enhanced Dynamic Range (EDR) technology, a rapid full-plate auto-focus and automatic luminescence cross-talk reduction. The EDR tech…

Vabysmo (faricimab-svoa) targets and inhibits two disease pathways that drive neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME) Vabysmo is the only injectable eye medicine approved simultaneously in the US for nAMD and DME, with flexible dosing regimens based on patient need Basel, 31 January 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved Vabysmo™ (faricimab-svoa) for the treatment of neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME). Neovascular AMD and DME are two leading causes of vision loss worldwide.1 Vabysmo targets and inhibits two disease pathways linked to a number of vision-threatening retinal conditions by neutralisin…

Parenteral and device manufacturing site will increase the number of people around the world who may benefit from Lilly's medicines INDIANAPOLIS, Jan. 28, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) plans to invest over $1 billion to create a new manufacturing site, along with nearly 600 new jobs in Concord, North Carolina. The brand-new facility will utilize the latest technology to manufacture parenteral (injectable) products and devices and increase the company's manufacturing capacity. "Lilly is entering an exciting period of growth and we are committed to delivering innovative medicines to patients around the world," said Edgardo Hernandez, senior vice president and president, Lilly Manufacturing Operations. "Expanding our manufacturing footprint in North Carolina enables…

Idorsia to capitalize upon the unique opportunity to transform the insomnia treatment paradigm, notably in Europe where daridorexant would be the first dual orexin receptor antagonist made available to patients with insomnia Collaboration with Syneos Health to effectively reach the primary care market in Europe and Canada Allschwil, Switzerland & Morrisville, N.C. – January 26, 2022Idorsia Ltd (SIX: IDIA), a leading Swiss biopharmaceutical company, and Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the extension of an existing collaboration to commercialize daridorexant, a novel dual orexin receptor antagonist for the treatment of insomnia across Europe and Canada. Simon Jose, Chief Commercial Officer of Idorsia, comm…

Merger continues commitment to innovation and strengthens tech-enablement and automation Frankfurt, Germany – 25 January 2022: PharmaLex Group, a leading provider of specialized services for the pharma, biotech and medtech industries worldwide, has announced a merger with leading technology and services organization for clinical and regulatory solutions, Phlexglobal. Founded in 1997, Phlexglobal provides its industry-leading and innovative electronic Trial Master File platform (PhlexTMF) and services to hundreds of global life sciences companies and AI-enabled automation solutions that allow customers to benefit from existing clinical and regulatory training models.   Phlexglobal’s staff of more than 400 people – based in the United Kingdom, the United States, India, Poland and Germany – b…

DUBAI, Arab Emirates, January 21, 2022 (Newswire.com) - AiPharma, a global biopharmaceutical company developing and commercializing innovative antiviral therapies, has completed an extensive rebranding effort in response to accelerated company growth and to reflect the business's expanded strategy. The company has undergone a significant transformation at the beginning of 2022 and has decided to relaunch its business under the new brand name Cellvera. The name Cellvera, originated from Latin, breaks down to 'cell' - which is referred to as the smallest yet fundamental unit of life in which the DNA code is being stored, and 'vera' which means true. This name represents the company and aligns with its beliefs and approach towards the science in which lies the truth of life and health encoded…

Achieved Global Recognition And Top Employer Certification In 39 Countries From Top Employers Institute® Recognition Highlights Takeda’s Unwavering Commitment To Its People OSAKA, Japan and CAMBRIDGE, Massachusetts, January 19, 2022 – Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it was one of only 11 companies to achieve global Top Employer® certification for 2022, marking the fifth consecutive year that it has been recognized for outstanding people policies and practices worldwide. In addition to the global certification, Takeda is also recognized as a Top Employer across four regions and 39 countries, reinforcing its steadfast commitment to create a diverse and inclusive organization that enables its people to thrive.    Established more…

Boehringer Ingelheim advances to one of eleven global top employers worldwide  Awards in 29 countries and in Europe, the Latin America, and Asia-Pacific regions  High scores in values, ethics and integrity serve as a driver for a strong corporate innovation culture  Ingelheim, Germany, January 20, 2022 – The Top Employers Institute awarded Boehringer Ingelheim for the second year in succession a “Global Top Employer”, one of the world’s eleven best employers. The award shows that the research-driven pharmaceutical company is strongly oriented to the needs and well-being of its employees. Boehringer Ingelheim has been listed among the top employers in many countries and regions for the past eight years. This year, Boehringer Ingelheim will receive the award in 29 countries, as well as…

Merger extends reach in key Italian marketplace and broadens market access expertise  Frankfurt, Germany – January 18th 2022: PharmaLex Group, a leading provider of specialized services for the pharma, biotech and medical device industries worldwide, has announced a merger with MAP Group, Italy’s leading provider of market access services.  Founded in 2010 by Elena Paola Lanati, MAP Group comprises three companies: MA Provider, MAPCOM Consulting and 3P Solution, which together deliver high-quality expertise across the product life cycle -- from negotiation strategy, to local market access, to market launch.  MAP Group’s staff of more than 70 experts support a large number of new drugs for market entry in Italy, providing integrated market access, communication and educational services. The…

COLLABORATION LEVERAGES EVOTEC'S BROAD METABOLIC EXPERTISE AND UNIQUE KIDNEY DISEASE PATIENT DATABASE AS WELL AS INTEGRATED DATA-DRIVEN DRUG DISCOVERY AND DEVELOPMENT PLATFORMS LILLY HAS THE RIGHT TO SELECT UP TO FIVE PROGRAMMES Hamburg, Germany, 18 January 2022:Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has entered into a drug discovery collaboration with Eli Lilly and Company ("Lilly") in the field of metabolic diseases with a focus on kidney diseases and diabetes.The collaboration leverages Evotec's extensive experience and track record of delivering in the field of metabolic diseases, as well as its unique and extensive kidney disease patient database, to identify and validate promising novel targets for th…

Enables sharing of, and access to, novel datasets and tools through Eagle Genomics’ e[datascientist]™ platform Agreement will facilitate understanding of complex relationships between microbiome, food and other factors, including potential causes of health and disease Cambridge and Norwich, UK – 13 January 2022 - Today, Eagle Genomics, the Deep Tech software business pioneering the application of network science to biology, and the Quadram Institute, a world-leading institute creating new interfaces between food science, gut biology, and human health, are pleased to announce a new partnership committed to promoting the understanding of microbiome science. Building on the agreement announced in September 2021 with the Earlham Institute, a Norwich-based leader in data-intensive bioscience…

Scholarships assist students pursuing STEM fields at Historically Black Colleges and Universities (HBCUs) Supports Black and Brown teachers to boost retention and quality in the classroom Mentorship opportunities with Baxter employees will further extend impact   WASHINGTON and DEERFIELD, Ill. - 2022-01-13 The Thurgood Marshall College Fund (TMCF), the largest organization exclusively representing the Black College community, and the Baxter International Foundation, the philanthropic arm of Baxter International Inc. (NYSE:BAX), introduced today a new collaboration called the Baxter HBCU STEM Scholars Program. The three-year, $3.5 million initiative funds scholarships and mentoring as part of a multi-faceted approach to support students at Historically Black Colleges and Univ…

Handheld blood glucose management device designed around the specific needs of healthcare professionals working in a range of care settings First diagnostic solution at the point of care to serve as a digital platform connecting developers of digital health software and applications to healthcare professionals New system simplifies workflows and equips healthcare professionals with valuable clinical insights to deliver better patient care Basel, 12 January 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the cobas® pulse system in select countries accepting the CE Mark. The cobas® pulse system marks Roche Diagnostics’ newest generation of connected point of care solutions for professional blood glucose management. As an industry first, the cobas® pulse system combi…

The new company is focused on developing GP-2250, a novel cancer therapeutic with a unique mechanism of action BERWYN, Pa.--(BUSINESS WIRE)--Panavance Therapeutics Inc. (“Panavance”) is a new clinical-stage pharmaceutical company created to advance and develop GP-2250, a patented, novel therapeutic for the treatment of cancer and other therapeutic indications. GP-2250 is a broadly active, tumor cell selective cancer therapeutic with a unique mechanism of action that, as demonstrated in preclinical research, suppresses cancer cells by disrupting their energy metabolism—bringing about cancer cell death. Panavance’s initial clinical focus is on pancreatic cancer, and the company is conducting preclinical studies to develop GP-2250 for the treatment of other cancers and therapeutic indications…

Agreement Announced on the Australian Stock Exchange and SIX Swiss Exchange 14 December, 2021 Expands CSL’s leadership across an attractive portfolio focused on Renal Disease, and Iron Deficiency Complements CSL’s existing therapeutic focus areas including Hematology and Thrombosis, Cardiovascular-Metabolic, and Transplant, and high quality pipeline CSL’s global scale, R&D capabilities and resources augment the delivery of Vifor Pharma’s products to patients globally All-cash tender offer of US$179.25 per Vifor Pharma share, representing an aggregate equity value for Vifor Pharma of US$11.7 billion / A$16.4 billion1 Tender offer is unanimously recommended for acceptance by Vifor Pharma's Board of Directors Patinex AG, Vifor Pharma's largest shareholder holding 23% of Vifor Pharma’s sh…

Accelerates the company's vision for transforming healthcare and advancing patient care worldwide – from the hospital to the home Combination creates opportunities for innovation that should drive efficiencies across care settings and help improve care outcomes Complementary products and pipeline enable broader access to care globally Expected to generate high single-digit ROIC by year five and approximately $250 million of annual pre-tax cost synergies by the end of year three  Positions Baxter for anticipated faster top- and bottom-line growth DEERFIELD, Ill. - 2021-12-13 Baxter International Inc. (NYSE:BAX), a global medtech leader, announced today it has completed its acquisition of Hillrom. Baxter paid $156.00 in cash for each outstanding share of Hillrom common sto…